Free Access
Med Sci (Paris)
Volume 20, Number 1, Janvier 2004
Page(s) 19 - 21
Section Nouvelles
Published online 15 January 2004
  1. Pardoll D. T cells and tumors. Nature 2001; 411 : 1010–2. [Google Scholar]
  2. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411 : 380–4. [Google Scholar]
  3. Blackburn EH. Telomerases. Annu Rev Biochem 1992; 61 : 113–29. [Google Scholar]
  4. Counter CM, Avilion AA, LeFeuvre CE, et al. Telomere shortening associated with chromosome instability is arrested in immortal celles which express telomerase activity. EMBO J 1992; 11 : 1921–9. [Google Scholar]
  5. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal celles an cancer. Science 1994; 266 : 2011–5. [Google Scholar]
  6. Broccoli D, Young JW, de Lange T. Telomerase activity in normal an malignant hematopoietic cells. Proc Natl Acad Sci USA 1995; 92 : 9082–6. [Google Scholar]
  7. Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor celles an during immortalization. Cell 1997; 90 : 785–95. [Google Scholar]
  8. Kim NW. Clinical implications of telomerase in cancer. Eur J Cancer 1997; 33 : 781–6. [Google Scholar]
  9. Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast an human. Science 1997; 277 : 955–9. [Google Scholar]
  10. Shay JW, Wright WE. Telomerase : a target for cancer therapeutics. Cancer Cell 2002; 2 : 257–65. [Google Scholar]
  11. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10 : 673–9. [Google Scholar]
  12. Minev B, Hipp J, Firat H, et al. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 2000; 97 : 4796–801. [Google Scholar]
  13. Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, Nadler LM. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res 2001; 7 : 3343–8. [Google Scholar]
  14. Vonderheide RH, Schultze JL, Anderson KS, et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res 2001; 61 : 8366–70. [Google Scholar]
  15. Nair SK, Heiser A, Boczkowski D, et al. Induction of cytotoxic T cell responses an tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000; 6 : 1011–7. [Google Scholar]
  16. Nanda NK,Sercarz EE. Induction of anti-self-immunity to cure cancer. Cell 1995 14; 82 : 13–7. [Google Scholar]
  17. Houghton AN. Cancer antigens : immune recognition of self an altered self. J Exp Med 1994; 180 : 1–4. [Google Scholar]
  18. Vonderheide RH. Telomerase as a universel tumor-associated antigen for cancer immunotherapy. Oncogene 2002; 21 : 674–9. [Google Scholar]
  19. Hernandez J, Garcia-Pons F, Lone YC, et al. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor celles. Proc Natl Acad Sci USA 2002; 99 : 12275–80. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.